Clinical Trial: Immune Modulation Therapy for Pompe Disease

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Immune Modulation Therapy for ERT-naïve or ERT-treated Pompe Disease Patients

Brief Summary: The purpose of this study is to assess anti-recombinant human acid α-glucosidase (anti-rhGAA) antibody titers after treatment with immune modulation therapy in patients of Pompe disease.

Detailed Summary:
Sponsor: National Taiwan University Hospital

Current Primary Outcome: anti-recombinant human acid α-glucosidase (anti-rhGAA) antibody titers decrease [ Time Frame: 6 months ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: National Taiwan University Hospital

Dates:
Date Received: August 10, 2015
Date Started: August 2015
Date Completion: July 2020
Last Updated: April 13, 2016
Last Verified: April 2016